<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191252</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-TMB</org_study_id>
    <nct_id>NCT04191252</nct_id>
  </id_info>
  <brief_title>Genetic Mutation in Epithelial Ovarian Cancer</brief_title>
  <official_title>Overall Perspective on the Characteristics of Genetic Mutation in Chinese Patients of Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about the characteristics of genetic mutation in a large multi-gene panel in
      epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a
      multi-gene panel, which consists of more than 500 hundred genes. The mutation characteristics
      are to be revealed in single nucleotide variants, copy number variations, insertion-deletion
      variations, and genomic structural variations. The total mutation burden (TMB) will be
      calculated. The status of microsatellite instability, expression of PD-1 and PD-L1 antibodies
      are also tested. These findings will be studies in association with the patients' prognosis
      and sensitivity to platinum-based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of genetic mutations</measure>
    <time_frame>Two years</time_frame>
    <description>Frequency of various genetic mutations among recruited patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mutation burden</measure>
    <time_frame>Two years</time_frame>
    <description>Total mutation burden calculated in definite patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of microsatellite Instability</measure>
    <time_frame>Two years</time_frame>
    <description>Microsatellite Instability in definite patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression rates of PD-1 and PD-L1 antibodies</measure>
    <time_frame>Two years</time_frame>
    <description>Expression rates of PD-1 and PD-L1 antibodies among recruited patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Nucleotide Variant</condition>
  <condition>Copy Number Variation</condition>
  <condition>Insertion-deletion Variation</condition>
  <condition>Genomic Structural Variation</condition>
  <condition>Total Mutation Burden</condition>
  <condition>Microsatellite Instability</condition>
  <condition>PD-1</condition>
  <condition>PD-L1</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>A multi-gene panel testing</intervention_name>
    <description>A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood and paired tumor tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of pathology confirmed of epithelial ovarian cancer and aged 18 years or older
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or
             adenosquamous carcinoma

          -  With available materials for analysis

          -  With detailed clinicopathological information

          -  Given consent to participate the trial

        Exclusion Criteria:

          -  Not meeting all of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

